Kraig Biocraft Laboratories Leverages New Production Center for Largest Ever Batch of Spider Silk Parental Lines

Rhea-AI Summary

Kraig Biocraft Laboratories (OTCQB: KBLB) has launched its largest production cycle of the BAM-1 spider silk line, more than doubling its previous single-batch caterpillar production record. The company is leveraging its new production rearing center to maximize capacity. The batch is divided into two groups:

1. 20% BAM-1 hybrids for reeling finished silk
2. 80% split evenly between two BAM-1 parental lines for crossbreeding

This strategy aims to quickly ramp up first-generation BAM-1 hybrid egg production. The record-setting cycle demonstrates Kraig Labs' commitment to scaling up production of advanced silk materials, positioning the company to meet diverse market needs and move closer to full-scale commercial production.

Positive

• Largest ever production cycle of BAM-1 line, more than doubling previous record
• Expanded capacity through new production rearing center
• Strategic focus on parental lines to rapidly increase first-generation hybrid egg production
• Positioning for full-scale commercial production of spider silk materials

Negative

• None.

ANN ARBOR, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), the leading developer of commercially viable spider silk, today proudly announces the launch of its largest production cycle of its BAM-1 line. Leveraging the expanded capacity of its new production rearing center, this rearing cycle will more than double the Company's previous single-batch caterpillar production record.

To grow production capacity and maximize the new rearing center, the Company has divided this batch into two groups. Twenty percent of this batch are BAM-1 hybrids for reeling finished silk. Eighty percent of this batch is split evenly between the two BAM-1 parental lines that will be crossbred to produce millions of BAM-1 hybrid silkworm eggs for future production cycles.

First-generation hybrids are created by crossbreeding the two BAM-1 parental lines together. These first-generation hybrids create larger production cocoons, increased robustness, and improved reeling performance. As such, the Company maintains a small population of its BAM-1 parental lines that are raised in parallel with the BAM-1 hybrids each production cycle. The priority placed on BAM-1 parental lines for this rearing cycle was explicitly targeted to quickly ramp up first-generation BAM-1 hybrid eggs.

This record-setting production cycle highlights the Company's ongoing commitment to scaling up the production of its advanced silk materials, bringing Kraig Labs one step closer to revolutionizing the performance materials market.

This production batch marks a significant increase in both the volume and scale of the Company's silkworm-based spider silk manufacturing, ensuring that Kraig Labs is well-positioned to meet the needs of these broad and diverse markets.

"This milestone BAM-1 production run exemplifies our commitment to scaling the production of our unique spider silk fibers," said Company Founder and CEO, Kim Thompson. "As we continue to break new ground in performance materials, this expanded capacity represents a key advancement toward full-scale commercial production."

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

FAQ

What is the significance of Kraig Biocraft Laboratories' latest BAM-1 production cycle?

Kraig Biocraft Laboratories' (KBLB) latest BAM-1 production cycle is significant because it's the largest ever, more than doubling their previous single-batch caterpillar production record. This demonstrates the company's ability to scale up production of their spider silk materials.

How is Kraig Biocraft Laboratories (KBLB) leveraging its new production rearing center?

Kraig Biocraft Laboratories is leveraging its new production rearing center to maximize capacity. They've divided the batch into two groups: 20% for BAM-1 hybrids for finished silk reeling, and 80% split between two BAM-1 parental lines for crossbreeding to produce millions of hybrid eggs for future cycles.

What is the purpose of Kraig Biocraft Laboratories' focus on BAM-1 parental lines in this production cycle?

The focus on BAM-1 parental lines in this production cycle is explicitly targeted to quickly ramp up first-generation BAM-1 hybrid egg production. This strategy aims to increase the volume of hybrid silkworms, which produce larger cocoons with improved robustness and reeling performance.

How does this production cycle impact Kraig Biocraft Laboratories' (KBLB) commercial prospects?

This record-setting production cycle positions Kraig Biocraft Laboratories (KBLB) to better meet the needs of broad and diverse markets. It represents a key advancement toward full-scale commercial production of their unique spider silk fibers, potentially revolutionizing the performance materials market.